SAB Biotherapeutics (SABS) AI Stock Analysis

• Market Cap: $182.81M
• Dividend Yield: N/A
• Average Volume (3M): 398.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: -92.42%
• EPS Growth: 62.37%
• Country: US
• Employees: 63
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 47,606,850
• 10 Day Avg. Volume: 357,955
• 30 Day Avg. Volume: 398,221
• PEG Ratio: 0.02
• Price to Book (P/B): 1.35
• Price to Sales (P/S): 26.55
• P/FCF Ratio: -1.01
• Enterprise Value/Market Cap: 0.09
• Enterprise Value/Revenue: 148.36
• Enterprise Value/Gross Profit: -5.60
• Enterprise Value/Ebitda: 0.77
• 1Y Price Target: $12.00
• Price Target Upside: 212.50% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $3.50 ▼(-8.85% Downside)

The overall stock score is primarily impacted by significant financial challenges, including declining revenues and negative cash flows. While technical analysis shows bullish momentum, poor valuation metrics and financial performance weigh heavily on the score.

Positive Factors

Strategic Partnerships

Partnerships with government entities provide stable funding and support for product development, enhancing long-term revenue potential.

Proprietary Platform

A unique platform for polyclonal antibodies offers a competitive edge in biopharmaceuticals, potentially leading to innovative treatments.

Product Pipeline

A diverse pipeline with candidates in development stages positions the company for future growth and market expansion.

Negative Factors

Revenue Decline

Significant revenue decline indicates challenges in product commercialization and market penetration, affecting long-term growth.

Cash Flow Challenges

Negative cash flow impacts the ability to fund operations and invest in growth, posing risks to financial stability.

High Debt Levels

High debt levels can strain financial resources and limit flexibility, potentially hindering strategic initiatives.

SAB Biotherapeutics Business Overview & Revenue Model

Company Description

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

How the Company Makes Money

SAB Biotherapeutics generates revenue through multiple channels, including government and private sector grants, partnerships with pharmaceutical companies for the development and commercialization of its therapeutic products, and potential product sales once therapies are approved and brought to market. The company has established significant collaborations with organizations such as the U.S. government for funding and support in developing treatments, which contribute to its revenue streams. Additionally, SAB may earn royalties or milestone payments from partners as products progress through clinical trials and achieve regulatory approvals.

SAB Biotherapeutics Financial Statement Overview

Summary

SAB Biotherapeutics faces significant financial challenges, with declining revenues, persistent losses, and cash flow difficulties. The balance sheet shows some stability, but the negative cash flow and profitability metrics highlight the need for strategic improvements.

Income Statement

SAB Biotherapeutics has experienced a significant decline in revenue over recent years, with total revenue falling from $60.88 million in 2021 to just $1.32 million in 2024. The company has maintained negative EBIT and net income, indicating ongoing operational challenges. Margins have remained weak, with a negative net profit margin, reflecting persistent losses.

Balance Sheet

The company's balance sheet shows a relatively high debt-to-equity ratio, indicating a reliance on debt financing. However, the equity ratio remains reasonable, suggesting some level of financial stability. Stockholders' equity has decreased over the years, which could be a concern if this trend continues.

Cash Flow

SAB Biotherapeutics has faced challenges in generating positive operating cash flow, with significant negative free cash flow in recent years. The company has also shown volatility in financing cash flows, suggesting potential difficulties in maintaining liquidity and funding operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	114.70K	1.32M	2.24M	23.90M	60.88M	55.24M
Gross Profit	-3.04M	-3.47M	-1.51M	20.61M	59.22M	55.24M
EBITDA	22.14M	-28.99M	-38.13M	-15.12M	-15.20M	21.14M
Net Income	-21.37M	-34.11M	-42.19M	-18.74M	-17.14M	20.12M
Balance Sheet
Total Assets	183.45M	44.20M	83.94M	50.90M	81.14M	56.54M
Cash, Cash Equivalents and Short-Term Investments	110.88M	20.76M	56.57M	15.05M	33.21M	12.61M
Total Debt	6.19M	4.67M	5.91M	5.93M	8.52M	8.13M
Total Liabilities	18.37M	18.23M	26.64M	19.85M	42.59M	17.53M
Stockholders Equity	165.07M	25.97M	57.30M	31.06M	38.55M	39.01M
Cash Flow
Free Cash Flow	-37.33M	-34.63M	-25.32M	-25.63M	-8.96M	-2.73M
Operating Cash Flow	-37.27M	-34.29M	-25.12M	-23.46M	1.99M	10.00M
Investing Cash Flow	-110.67M	-11.96M	-152.70K	-2.09M	-10.94M	-12.72M
Financing Cash Flow	168.30M	-1.17M	66.77M	1.05M	35.89M	8.98M

SAB Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SABS, the sentiment is Positive. The current price of 3.84 is above the 20-day moving average (MA) of 3.84, above the 50-day MA of 3.46, and above the 200-day MA of 2.32, indicating a bullish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 54.10 is Neutral, neither overbought nor oversold. The STOCH value of 59.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SABS.

SAB Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SABS	52 Neutral	$182.81M	-1.24	-21.16%	―	-92.42%	62.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LSTA	43 Neutral	$18.08M	-0.96	-71.45%	―	―	15.32%
SNSE	40 Underperform	$11.68M	-0.43	-67.47%	―	―	9.63%
NXTC	36 Underperform	$44.84M	-0.53	-116.91%	―	―	3.78%
RLYB	35 Underperform	$30.91M	-2.29	-21.17%	―	12.71%	79.93%
LPTX	31 Underperform	―	―	-196.76%	―	―	36.27%

SAB Biotherapeutics Corporate Events

SAB Biotherapeutics Board Members Resign in Agreement

On September 30, 2025, Christine Hamilton and Jeffrey Spragens resigned from the Board of Directors of SAB Biotherapeutics, Inc., reducing the Board’s size from 11 to nine members. This change was in line with an agreement with RA Capital Healthcare Fund, L.P., following a private placement of securities in July 2025. The resignations were not due to any disagreements with the company, and the Board expressed gratitude for their service.

SAB Biotherapeutics Approves Equity Plan Amendments

On September 26, 2025, SAB Biotherapeutics held a special meeting where stockholders approved amendments to the company’s 2021 Omnibus Equity Incentive Plan, significantly increasing the number of shares available for participants. Additionally, stockholders approved the potential issuance of shares exceeding 19.99% of the company’s outstanding stock upon conversion of Series B Convertible Preferred Stock, which may be considered a ‘change of control’ under Nasdaq rules.